▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2303 by analyst upside · 2026-09-27
CVS
CVS Health Corporation
Healthcare · Market Cap $114B · P/E 23.5x
ANALYST PRICE TARGET
+30.5%
implied upside to consensus target
Current Price $89.13
Consensus Target $116.28
Bull Target $148.0
Bear Target $103.0
Analysts Covering 25
ANALYST CONSENSUS - BUY
Strong Buy
6
Buy
17
Hold
2
Sell
0
52-Week Low $69.51
52-Week High $110.68
YTD Return +13.8%
FUNDAMENTALS
Market Cap $114B
P/E Ratio (TTM) 23.5x
Forward P/E 10.5x
EPS (TTM) $3.79
PEG Ratio 0.21
Dividend Yield 2.98%
Revenue (TTM) $412.6B
Profit Margin 1.2%
52-WEEK RANGE
52-Week Low $69.51
52-Week High $110.68
Current Price $89.13
Bear Target $103.0
Bull Target $148.0
● Now $89.13 ● Target $116.28
TRADING DATA
Avg Volume 7.4M
YTD Return +13.8%
Analyst Count 25
Consensus Buy
Upside to Target +30.5%
Last Updated 2026-09-27

ANALYST SUMMARY

CVS Health Corporation (CVS) is currently trading at $89.13 with a Wall Street consensus price target of $116.28, implying potential upside of 30.5% over the next 12 months. 25 analysts currently cover CVS, with a consensus rating of Buy - 92% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $148.0, while the most cautious has a target of $103.0.

CVS operates in the Healthcare sector with a market capitalisation of $114B. The stock is up 13.8% year-to-date and is currently trading near the lower end of its 52-week range of $69.51 – $110.68.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CVS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Buy → Buy 2026-09-03 33% win rate (6 calls)
Argus Research - Reiterated
Buy → Buy 2026-08-19 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-08-12 43% win rate (7 calls)
UBS - Reiterated
Buy → Buy 2026-08-06 33% win rate (6 calls)
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-08-06 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-08-06 Building track record
UBS - Reiterated
Buy → Buy 2026-07-25 33% win rate (6 calls)
Truist Securities - Reiterated
Buy → Buy 2026-07-14 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
67
out of 100
Coverage depth
25/30
Consensus clarity
20/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →